<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04163991</url>
  </required_header>
  <id_info>
    <org_study_id>VIB4920.P2.S3</org_study_id>
    <secondary_id>2019-003697-70</secondary_id>
    <nct_id>NCT04163991</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Efficacy of VIB4920 in Participants With Rheumatoid Arthritis</brief_title>
  <acronym>MIDORA</acronym>
  <official_title>A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Mechanistic Insight and Dosage Optimization Study of the Efficacy and Safety of VIB4920 in Patients With Rheumatoid Arthritis (RA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Viela Bio</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Viela Bio</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of
      VIB4920 (formerly MEDI4920) in adult participants with Rheumatoid Arthritis (RA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The overall study period will be approximately 337 days. After a screening period of up to 28
      days, the participants will be randomized in a 1:1:1:1:1 ratio to receive intravenous dose of
      VIB4920 and/or placebo in 5 cohorts. Participants are to be followed on their stable
      background anti-rheumatoid arthritis (RA) therapy at least through 12 weeks (Day 85), at
      which time rescue therapy may be instituted. All participants will be followed at least
      through the primary (interim) analysis (Day 113), and those who have not instituted rescue
      therapy will be followed through Day 309 to determine the duration of clinical response. The
      primary analysis will be after all participants have completed Day 113, and the final
      analysis will be after all participants have completed follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 9, 2019</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to Day 113 in Disease Activity Score in 28 Joints Using C-reactive Protein (DAS28-CRP) (range: 1-10; higher score is worse outcome)</measure>
    <time_frame>Day 1 (Baseline) through Day 113</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs), and Treatment-emergent Adverse Events of Special Interest (TEAESIs)</measure>
    <time_frame>Day 1 (Baseline) through Day 309</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of VIB4920</measure>
    <time_frame>Day 1 to Day 225</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Soluble Cluster of Differentiation 40 (sCD40L) Plasma Concentration</measure>
    <time_frame>Day 1 (Baseline) through Day 309</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Positive Anti-drug Antibodies (ADA) Titre to VIB4920</measure>
    <time_frame>Day 1 (Baseline) to Day 309</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Rheumatoid Factor (RF) From Baseline to Day 113</measure>
    <time_frame>Day 1 (Baseline) through Day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Anti-citrullinated Protein Antibodies (ACPAs) From Baseline to Day 113</measure>
    <time_frame>Day 1 (Baseline) through Day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Clinical Remission at Day 113</measure>
    <time_frame>Day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Start of New Treatment for RA</measure>
    <time_frame>Day 1 (Baseline) through Day 309</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>VIB4920 Dose1 (dosing interval 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive intravenous (IV) infusion of VIB4920 Dose1 in dosing interval 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VIB4920 Dose1 (dosing interval 2)+Placebo (dosing interval 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive IV infusion of VIB4920 Dose1 in dosing interval 2 and placebo matched to VIB4920 in dosing interval 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VIB4920 Dose2 (dosing interval 2)+Placebo (dosing interval 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive IV infusion of VIB4920 Dose2 in dosing interval 2 and placebo matched to VIB4920 in dosing interval 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VIB4920 Dose2 (dosing interval 4)+Placebo (dosing interval 5)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive IV infusion of VIB4920 Dose2 in dosing interval 4 and placebo matched to VIB4920 in dosing interval 5.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (dosing interval 1)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive IV infusion of placebo matched to VIB4920 in dosing interval 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VIB4920</intervention_name>
    <description>VIB4920 Dose 1 or 2 will be administered intravenously per dosing interval of 1 or 2 or 4.</description>
    <arm_group_label>VIB4920 Dose1 (dosing interval 1)</arm_group_label>
    <arm_group_label>VIB4920 Dose1 (dosing interval 2)+Placebo (dosing interval 3)</arm_group_label>
    <arm_group_label>VIB4920 Dose2 (dosing interval 2)+Placebo (dosing interval 3)</arm_group_label>
    <arm_group_label>VIB4920 Dose2 (dosing interval 4)+Placebo (dosing interval 5)</arm_group_label>
    <other_name>MEDI4920</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered intravenously per dosing interval of 1 or 3 or 5.</description>
    <arm_group_label>Placebo (dosing interval 1)</arm_group_label>
    <arm_group_label>VIB4920 Dose1 (dosing interval 2)+Placebo (dosing interval 3)</arm_group_label>
    <arm_group_label>VIB4920 Dose2 (dosing interval 2)+Placebo (dosing interval 3)</arm_group_label>
    <arm_group_label>VIB4920 Dose2 (dosing interval 4)+Placebo (dosing interval 5)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Principal Inclusion Criteria:

          1. Male or female adults, &gt;= 18 years of age at time of informed consent.

          2. Diagnosed with RA according to the European League Against Rheumatism/American College
             of Rheumatology (EULAR/ACR) 2010 criteria &gt;= 6 months prior to screening.

          3. Disease Activity Score in 28 Joints using C-reactive Protein (DAS28-CRP) &gt; 3.2 at
             screening with &gt;= 4 tender joint count (TJC) and &gt;= 4 swollen joint count (SJC) out of
             the 28 joints assessed for DAS28 present at screening and confirmed present at visit 2
             prior to randomization.

          4. Positive for RF and/or ACPA at screening, in accordance with criteria at the central
             laboratory.

          5. Treated with methotrexate (MTX), with or without a concomitant conventional
             disease-modifying anti-rheumatic drug (cDMARD).

          6. Agreeing to use of protocol defined contraception methods.

        Principal Exclusion Criteria:

          1. Prior or current inflammatory joint disease other than RA.

          2. Severe interstitial lung disease.

          3. Prior receipt of any biologic B-cell-depleting therapy.

          4. Receipt of any anti - tumor necrosis factor alpha (TNF-α) biologic agent &lt; 8 weeks
             prior to screening.

          5. Receipt of any biologic disease-modifying anti-rheumatic drug (bDMARD) with a
             mechanism of action other than direct TNF- α blockade, &lt; 12 weeks or &lt; 5 half-lives of
             the drug prior to screening.

          6. Injectable corticosteroids or treatment with &gt; 10 mg/day dose of oral prednisolone or
             equivalent within 4 weeks prior to screening.

          7. Previous treatment with anti-CD40L compounds at any time before randomization.

          8. Hepatitis B, hepatitis C, or human immunodeficiency virus infection.

          9. Pregnant or lactating or planning to get pregnant during the duration of the study.

         10. Evidence of active tuberculosis (TB) or being at high risk for TB.

         11. History of more than one episode of herpes zoster in the 12 months prior to screening
             or any opportunistic infection in the 12 months prior to screening, excluding
             localized mucocutaneous candidiasis.

         12. Receipt of live vaccine or live therapeutic infectious agent within the 4 weeks prior
             to screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Judith Falloon, MD</last_name>
    <role>Study Director</role>
    <affiliation>Viela Bio</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <zip>91786</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zephyrhills</city>
        <state>Florida</state>
        <zip>33542</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wheaton</city>
        <state>Maryland</state>
        <zip>20902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rocky Mount</city>
        <state>North Carolina</state>
        <zip>27804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <zip>28144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vandalia</city>
        <state>Ohio</state>
        <zip>45377</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <zip>73069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baytown</city>
        <state>Texas</state>
        <zip>77521</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>November 12, 2019</study_first_submitted>
  <study_first_submitted_qc>November 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2019</study_first_posted>
  <last_update_submitted>March 26, 2020</last_update_submitted>
  <last_update_submitted_qc>March 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>RA</keyword>
  <keyword>VIB4920</keyword>
  <keyword>MEDI4920</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

